Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors

被引:7
|
作者
Wefel, Jeffrey S. [1 ]
Ryan, Charles J. [2 ]
Van, Julie [3 ]
Jackson, James C. [4 ]
Morgans, Alicia K. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA
[3] Brigham Young Univ, Provo, UT 84602 USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Dana Farber Canc Inst, Survivorship Program, 450 Brookline Ave,DA 09-930, Boston, MA 02215 USA
关键词
QUALITY-OF-LIFE; MINI-MENTAL-STATE; ACETATE PLUS PREDNISONE; DEPRIVATION THERAPY; ABIRATERONE ACETATE; ACTIVITIES QUESTIONNAIRE; INTERNATIONAL SOCIETY; GERIATRIC ASSESSMENT; ALZHEIMERS-DISEASE; INCREASED SURVIVAL;
D O I
10.1007/s40263-022-00913-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Preservation of cognitive function is an important outcome in oncology. Optimal patient management requires an understanding of cognitive effects of the disease and its treatment and an efficacious approach to assessment and management of cognitive dysfunction, including selection of treatments to minimize the risk of cognitive impairment. Awareness is increasing of the potentially detrimental effects of cancer-related cognitive dysfunction on functional independence and quality of life. Prostate cancer occurs most often in older men, who are more likely to develop cognitive dysfunction than younger individuals; this population may be particularly vulnerable to treatment-related cognitive disorders. Prompt identification of treatment-induced cognitive dysfunction is a crucial aspect of effective cancer management. We review the potential etiologies of cognitive decline in patients with prostate cancer, including the potential role of androgen receptor pathway inhibitors; commonly used tools for assessing cognitive function validated in metastatic castration-resistant prostate cancer and adopted in non-metastatic castration-resistant prostate cancer trials; and strategies for management of cognitive symptoms. Many methods are currently used to assess cognitive function. The prevalence and severity of cognitive dysfunction vary according to the instruments and criteria applied. Consensus on the definition of cognitive dysfunction and on the most appropriate approaches to quantify its extent and progression in patients treated for prostate cancer is lacking. Evidence-based guidance on the appropriate tools and time to assess cognitive function in patients with prostate cancer is required. Plain Language Summary Men with prostate cancer are usually elderly and may have other health conditions. Old age, poor health, and some medications can all affect a person's ability to think clearly, make sound judgments, remember things, and learn new information. These mental difficulties can make it hard for people to do day-to-day tasks such as shopping or making a meal, looking after themselves, or taking medications correctly. People may also have problems with friendships and relationships. Therefore, before a man starts treatment for prostate cancer, he and his doctor must consider the likelihood that his mental ability might be affected by the treatment in order to choose the most suitable treatment option. Initially, the doctor can use short screening tests, such as asking the patient to remember and repeat numbers or words, draw objects, name things in a picture, or complete a survey. If these tests show that the patient might be having mental difficulties, he may be invited for additional tests with a specialist, called a neuropsychologist. A patient with, or at risk of, mental difficulties will be offered a care plan, which might include one or more of the following: selecting or switching treatments to avoid side effects; using memory aids; treatment for pain, difficulty sleeping, depression, or other problems that might affect mental function; sessions with a specialist to improve mental ability and develop techniques to adapt to worsening mental function; physical exercise; and getting help from others with household tasks, personal care, or taking medications.
引用
收藏
页码:419 / 449
页数:31
相关论文
共 50 条
  • [21] Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors
    Asiri, Ibrahim M.
    Chen, Ronald C.
    Master, Viraj
    Mi, Lanyu
    James, Sarah E.
    Bryce, Alan H.
    Afzal, Umar
    Riaz, Irbaz B.
    Naqvi, Syed Arsalan Ahmed
    Beach, Steven R. H.
    Cobran, Ewan K.
    PROSTATE, 2025,
  • [22] Drug Resistance and Cardiovascular Safety of Second-Generation Anti-Androgens in Patients with Advanced Prostate Cancer
    Raberi, Venus Shahabi
    Shariati, Akram
    Abbasnezhad, Mohsen
    Aslanabadi, Naser
    Abbasnezhad, Amirreza
    Bahmani, Amir
    GALEN MEDICAL JOURNAL, 2022, 11
  • [23] Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors
    Suzuki, Kotaro
    Shiraishi, Yusuke
    Furukawa, Junya
    Okamura, Yasuyoshi
    Bando, Yukari
    Hara, Takuto
    Okada, Keisuke
    Terakawa, Tomoaki
    Hyodo, Yoji
    Chiba, Koji
    Teishima, Jun
    Nakano, Yuzo
    Miyake, Hideaki
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [24] Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer
    Wang, Edina C.
    Lee, W. Robert
    Armstrong, Andrew J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 30 - 40
  • [25] Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors
    Fuerea, Alina
    Baciarello, Giulia
    Patrikidou, Anna
    Albiges, Laurence
    Massard, Christophe
    Di Palma, Mario
    Escudier, Bernard
    Fizazi, Karim
    Loriot, Yohann
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : 44 - 51
  • [26] Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis
    Matsukawa, Akihiro
    Yanagisawa, Takafumi
    Rajwa, Pawel
    Fazekas, Tamas
    Miszczyk, Marcin
    Tsuboi, Ichiro
    Parizi, Mehdi Kardoust
    Laukhtina, Ekaterina
    Klemm, Jakob
    Chiujdea, Sever
    Mancon, Stefano
    Mori, Keiichiro
    Kimura, Shoji
    Karakiewicz, Pierre I.
    Miki, Jun
    Kimura, Takahiro
    Shariat, Shahrokh F.
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [27] Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
    Ueda, Takashi
    Hayakawa, Keita
    Horiguchi, Go
    Murashita, Junki
    Shiraishi, Takumi
    Fujimoto, Saizo
    Miyashita, Masatsugu
    Saito, Yumiko
    Gabata, Yusuke
    Sako, Satoshi
    Takahashi, Hikaru
    Fujihara, Atsuko
    Minami, Takafumi
    Yamamoto, Yutaka
    Okumi, Masayoshi
    Hongo, Fumiya
    Okihara, Koji
    Fujita, Kazutoshi
    Ukimura, Osamu
    PROSTATE, 2025, : 524 - 530
  • [28] Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide
    Pan, Alexander
    Reingold, Rachel E.
    Zhao, Jimmy L.
    Moy, Andrea
    Kraehenbuehl, Lukas
    Dranitsaris, George
    McBride, Sean M.
    Scher, Howard, I
    Kollmeier, Marisa A.
    Xiao, Han
    Rathkopf, Dana E.
    Lacouture, Mario E.
    JOURNAL OF UROLOGY, 2022, 207 (05) : 1010 - 1019
  • [29] Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
    Rathkopf, D. E.
    Smith, M. R.
    Ryan, C. J.
    Berry, W. R.
    Shore, N. D.
    Liu, G.
    Higano, C. S.
    Alumkal, J. J.
    Hauke, R.
    Tutrone, R. F.
    Saleh, M.
    Maneval, E. Chow
    Thomas, S.
    Ricci, D. S.
    Yu, M. K.
    de Boer, C. J.
    Trinh, A.
    Kheoh, T.
    Bandekar, R.
    Scher, H. I.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2264 - 2271
  • [30] New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact
    Gasperoni, Lorenzo
    Giunta, Emilio Francesco
    Montanari, Daniela
    Masini, Carla
    De Giorgi, Ugo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (06) : 491 - 502